Our interest in the systematic review by Suzanne Ligthart and colleagues of published
studies evaluating the cost-effectiveness of drug-eluting stents 1 was not dispassionate, as …

Background: Drug-eluting stents have been seen as an attractive alternative to bare-metal
stents for percutaneous coronary interventions (PCIs) because of the decreased need for …

Drug-eluting stents have been developed to prevent in-stent restenosis following
percutaneous coronary revascularization. In a number of randomized trials, polymer-coated …

These results were confirmed by the pivotal TAXUS IV trial. 60 This large, prospective,
randomized, double-blind study randomized 652 patients who received a bare metal stent …

The availability of drug-eluting stents has resulted in a paradigm shift in the management of
patients with coronary artery disease with a substantial increase in the percentage of …

Drug-eluting stents have raised the current interventional practice to a new and higher level.
With the commercializa-tion of sirolimus-and paclitaxel-eluting stents in 2002 and 2003 …

Drug-eluting stents: the beginning of the end of restenosis? - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

Percutaneous transluminal coronary angioplasty revolutionized therapy for coronary artery
disease. This early promise of a viable alternative to surgical treatment of coronary artery …

The clinical and economic analysis by Eisenstein et al.(1) in this issue of JACC:
Cardiovascular Interventions is a welcome addition to the collective literature on the cost …

The major benefit of DES is a reduction in the rate of restenosis after PCI. Therefore, to
understand the clinical and economic impact of DES, the overall scope and consequences …